ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)
Zydus gets USFDA nod to market ointment for skin disorder
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Metronidazole Topical Cream, the drug maker said in a regulatory filing.
Zydus Lifesciences gets USFDA nod for generic medication
The company has got the final approval from the US Food and Drug Administration (USFDA) to market Icosapent Ethyl Capsules in strength of 0.5 g and 1 g, it said in a regulatory filing.
Zydus Lifesciences gets USFDA nod to its generic medicine for high BP
Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture and market its generic version of metoprolol tartrate tablets used to treat high blood pressure. The approval granted by the United States Food and Drug Administration (USFDA) is for metoprolol tartrate tablets of strengths 25 mg, 50 mg, and 100 mg, Zydus Lifesciences said in a regulatory filing. The drug will be manufactured at the group's formulation manufacturing facility at Baddi in Himachal Pradesh, it added. Metoprolol is used with or without other medications to treat high blood pressure (hypertension), the company said, adding the medication is also used to treat chest pain (angina) and to improve survival after a heart attack. Metoprolol tartrate tablets 25 mg, 50 mg, and 100 mg had annual sales of USD 45.2 million in the US, the company said citing IQVIA MAT February 2023 data.
Zydus Lifesciences stock hits new 52-week high on USFDA for pulmonary medicine
The stock hit its 52 week high of 519.70 in intraday trade on Wednesday.
Zydus' novel single dose malaria pill reaches phase 2 clinical trials
In Phase-2 trials now, pill also works against drug-resistant malaria strains ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)
Zydus Lifesciences gets USFDA nod to market generic drug
Zydus said the drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance under Regulation 76 of SEBI (DP) Regulations, 2018